ORIGINAL ARTICLE

Colonic mucosa-associated diffusely adherent \textit{afaC}+ \textit{Escherichia coli} expressing \textit{lpfA} and \textit{pks} are increased in inflammatory bowel disease and colon cancer

Maelle Prorok-Hamon,1 Melissa K Friswell,1 Abdullah Alswied,1 Carol L Roberts,1 Fei Song,1 Paul K Flanagan,1 Paul Knight,1 Caroline Codling,2 Julian R Marchesi,2,3 Craig Winstanley,4 Neil Hall,5 Jonathan M Rhodes,1 Barry J Campbell1

ABSTRACT

Objective Colonic mucosa-associated \textit{Escherichia coli} are increased in Crohn’s disease (CD) and colorectal cancer (CRC). They variously haemagglutinate, invade epithelial cell lines, replicate within macrophages, translocate across M (microfold) cells and damage DNA. We investigated genes responsible for these effects and their co-association in colonic mucosal isolates.

Design A fosmid library yielding 968 clones was prepared in \textit{E coli} EPI300-T1 using DNA from a haemagglutinating CRC isolate, and resulting haemagglutinating clones were 454-pyrosequenced. PCR screening was performed on 281 colonic \textit{E coli} isolates from inflammatory bowel disease (IBD) (35 patients), CRC (21) and controls (24; sporadic polyps or irritable bowel syndrome).

Results 454-Pyrosequencing of fosmids from the haemagglutinating clones (\(n=8\)) identified the afimbrial adherin \textit{afa}-1 operon. Transfection of \textit{afa}-1 into \textit{E coli} K-12 predictably conferred diffuse adherence plus invasion of HEp-2 and I-407 epithelial cells, and upregulation of vascular endothelial growth factor. \textit{E coli} expressing \textit{afaC} were common in CRC (14/21, \(p=0.0009\)) and CD (9/14, \(p=0.005\)) but not ulcerative colitis (UC; 8/21) compared with controls (4/24). \textit{E coli} expressing both \textit{afaC} and \textit{lpfA} (relevant to M-cell translocation) were common in CD (8/14, \(p=0.0019\)) and CRC (14/21, \(p=0.0001\)), but not UC (6/21) compared with controls (2/24). \textit{E coli} expressing both \textit{afaC} and \textit{pks} (genotoxic) were common in CRC (11/21, \(p=0.0015\)) and UC (8/21, \(p=0.022\)), but not CD (4/14) compared with controls (2/24). All isolates expressed \textit{dsbA} and \textit{htrA} relevant to intra-macrophage replication, and 242/281 expressed \textit{finH} encoding type-1 fimbrial adherin.

Conclusions IBD and CRC commonly have colonic mucosal \textit{E coli} that express genes that confer properties relevant to pathogenesis including M-cell translocation, angiogenesis and genotoxicity.

INTRODUCTION

It is accepted that bacteria are involved in inflammatory bowel disease (IBD) pathogenesis but the mechanisms are poorly understood.1 An increase in mucosa-associated \textit{Escherichia coli} in Crohn’s disease (CD) has been found in both ileum2 3 and colon.4–7 Increased mucosa-associated \textit{E coli} have also been reported in colorectal cancer (CRC)5 8 and to a lesser extent in ulcerative colitis (UC).3–11 These \textit{E coli} typically adhere to and invade intestinal epithelial cells in culture and replicate within macrophages.12 13 Gentamicin treatment of CD intestinal biopsies followed by lysis and culture
implies the presence of intracellular E.coli, and E.coli DNA has been demonstrated within a majority of CD granulomas.

Designated as ‘adherent, invasive E. coli’ (AIEC), some of the properties of these E.coli have been associated with specific genes, particularly in studies of the ‘paradigm’ ileal AIEC, LF82. These include high-temperature requirement-A (htrA) and oxidoreductase disulfide bond-A protein (dsbA), which support intra-macrophage survival and long polar fimbrae (lpfA) involved in translocation across M cells of the follicle-associated epithelium (FAE). There is, however, no genotype that is consistent across all AIEC. Moreover, their invasion of epithelial cell lines in vitro varies between cell lines and is a property found in other E.coli including diffusely adherent E.coli (DAEC) and uropathogenic E.coli (UPEC).

We have previously shown that colonic mucosa-associated E.coli from CD and CRC commonly expressed haemagglutinins and that this correlated with their ability to adhere to and invade epithelial cell lines.

Recent studies show that E.coli possessing the polyketide synthase gene complex (pks) responsible for producing the genotoxin colibactin induce inflammation-associated CRC in mice and are commonly mucosa associated in sporadic CRC.

Here we have used a fosmid-clone library, based on genomic DNA derived from a colon cancer mucosal AIEC, to investigate the nature of the haemagglutinin gene(s), its relevance to the AIEC phenotype, and distribution among mucosal E.coli from IBD, CRC and controls. We also screened these isolates for htrA and dsbA, relevant to replication within macrophages, lpfA and finH relevant to M-cell translocation, a likely portal of entry for mucosal invasion in CD and for the pks gene complex, relevant to CRC pathogenesis.

**METHODS**

**Cell culture**

The human colon adenocarcinoma cell-line Caco2 (#86010202), Burkitt’s lymphoma cell-line Raji-B (#85011429) and J774A.1 murine macrophages (#91051511) were from ECACC (Wiltshire, UK). Human I-407 (CCL-6) and HEp-2 (CCL-23) cells were from the American Type Culture Collection (LGC Standard; Teddington, UK). Caco2-c1 cells, kindly provided by Dr Elisabet Gullberg (Linköping University, Sweden), were originally obtained from Dr Maria Rescigno (European Institute of Oncology; Milan, Italy). Caco2, Caco2-c1 and I-407 were cultured in DMEM, HEp-2 in MEM, Raji-B and J774A.1 in RPMI-1640; supplemented with 10% FBS, 4 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin and maintained at 37°C in 5% carbon dioxide.

**Generation of an E.coli library from a colon mucosa-associated haemagglutinating E.coli with the AIEC phenotype**

Using E.coli HM358, a haemagglutination-positive isolate from a CRC patient as the parent strain, a randomly sheared, non-biased fosmid library was constructed (CopyControl fosmid library kit; Epicentre, Wisconsin, USA). Genomic DNA extracted from HM358 (GenomiX Cell/Tissue kit; Talent; Italy) was sheared, end-repaired with 5'-phosphorylated blunt ends, 30–50 kb DNA fragments ligated to phosphatase-treated fosmid pCC1FOS and introduced into phase T1-resistant E.coli K-12 derivative EPI300-T1. E.coli clones were selected on Luria-Bertani chloramphenicol (12.5 μg/mL) agar.

**Haemagglutination assay**

E.coli clones were screened for haemagglutination of 1% group O human erythrocytes (NBS; Liverpool, UK) with haemagglutination-positive E.coli HM358 and haemagglutination-negative E.coli EPI300-T1/pCC1FOS as controls.

**454-Pyrosequencing**

Following the induction of high copy number of fosmids during bacterial growth (Epicentre copy-control auto-induction solution), clones from haemagglutination-positive E.coli were extracted using Qiafilter midi-kits (Qiagen; Crawley, UK). 454-Sequencing was performed using the GS-FLX Titanium Series (Roche-454 Life Science; Branford, USA). 454-Reads were assembled with Newbler.st.0.10 and protein-coding sequences identified with GeneMarkP.24,4 (http://exonbiology.gatech.edu/). Predicted open-reading frames and translated amino acids were subjected to BLASTP to identify homologies to operons. Gene representation was performed using Artemis (http://www.sanger.ac.uk/resources/software/artemis/).

Following sequence analysis, E.coli HM358 and all fosmid-containing haemagglutination-positive E.coli were screened by PCR for afimbral adhesin (afaC), P-fimbriae (papC), type-1 pilus (FimA/FimC1/FimH), outer-membrane protein-C (ompC) and flagellin (flaC). Primers and conditions are detailed in supplementary file S1 (available online only).

**Presence of afa operon in colonic mucosal E.coli strains**

A panel of 281 colonic mucosal E.coli previously isolated from 80 patients was studied; 71 from 14 CD patients, 51 from 21 UC patients, 120 from 21 CRC patients and 39 from 24 controls. IBD and control isolates were obtained from colonoscopic biopsy of non-ulcerated sigmoid colon, CRC isolates from biopsy of colonic mucosa of colon cancer patients. CRC isolates were screened by PCR for afaE subtype, was performed using primers to amplify afaC, present in all operons of the afimbrial adhesin family (afa-1,-2,-3,-5,-7,-8 and daa). 25 26 27

**Generation of an afa-1-expressing recombinant E.coli**

Following sequence identification of Afa-1 as the putative adhesin responsible for haemagglutination, purified fosmid was extracted from haemagglutination-positive clone E.coli 8H8. The complete afa-1 operon (6.8 kb) was isolated by Xbal/Spe restriction enzyme digest, purified by gel electrophoresis, ligated into pUC18 using T4 DNA-ligase and propagated in E.coli One-ShotTOP10 (Invitrogen) selected on 100 μg/mL ampicillin agar. pUCAf was then used to transform chemically competent E.coli EPI300-T1 containing empty fosmid, to allow direct comparison with E.coli 8H8. The presence and orientation of afa-1 within pUCAf were confirmed by PCR. Functional adhesin was confirmed by haemagglutination and adhesion to HEp-2 cells (see supplementary file S2, available online only).

**Diffuse adherence to HEp-2 cells**

The ability of E.coli isolates, fosmid and pUCAf-transformed constructs to mediate diffuse adherence to HEp-2 was assessed in the presence of 1% methyl-α-D-mannopyranoside to exclude
type-1 fimbriae-mediated adhesion, with DAEC C1845 included as positive control.

Adherence and invasion to intestinal epithelial cell lines
Adherence to, and invasion of, E. coli to HEp-2, I-407 and differentiated Caco2 cells (15d post-confluent) was assessed by gentamicin protection assay in the presence of methyl-a-D-mannopyranoside. Bacteria were cultured overnight on Luria-Bertani agar, with adherence and invasion calculated as the percentage of the original inoculum, and data expressed relative to wild-type AIEC HM358.

Real-time PCR for VEGF
Confluent I-407 cells (8×10⁵ cells/well) were serum-starved for 24 h and then infected for 4 h Multiplicity of infection 20 (MOI 20) with either CRC AIEC HM358, E. coli EPI300-T1/ pCC1FOS transformed with afa-1 operon (pUCAfa) or vector alone (pUC18), or DAEC C1845 (known to upregulate vascular endothelial growth factor (VEGF)). Total RNA was isolated (RNaseq kit; Qiagen) and quantified by NanoDrop. VEGF messenger RNA was assessed by quantitative PCR of first-strand synthesised complementary DNA (Roche, Burgess Hill, UK) in a Lightcycler480 system using human VEGF or β-actin specific primers (Eurogentec) and probes from the Roche Universal Probe Library (see online supplementary file S1, available online only).

Replication of E. coli within J774A.1 macrophages
Macrophages were seeded onto 24-well plates (10⁵ cells/well) for 24 h and infected (MOI 10) with either E. coli HM358, library clones or E. coli constructs in antibiotic-free media. Intra-macrophage replication was determined by recovery of intracellular bacteria from lysed gentamicin-treated cells after 6 h or 24 h, relative to intracellular numbers at 3 h.

Translocation through M cells in culture
Translocation through M cells, generated by co-culture of Caco2-c11 and Raji-B cells, was conducted as previously described. Successful M-cell generation was confirmed by translocation of CD E. coli HM605 and 0.5 μm yellow-green FluoroSpheres (Invitrogen). Trans-epithelial electrical resistance was monitored throughout.

Screening for intra-macrophage replication genes htrA and dsbA, lpfA and the genotoxin-producing pks pathogenicity island in colonic mucosal E. coli
PCR assays for genes relevant to AIEC intramacrophage survival and replication, dsbA and htrA, and the two major lpf operons (lpfA(Shigella) and lpfA(A. baumannii)) identified in ileal CD AIEC, were performed. PCR for pks prevalent in patients with IBD and CRC, was performed previously.

Statistics.
N is the total number of independent experiments performed, with n replicates for each treatment group. Independent groups were assessed for normality and equality of variance, and analysed using Mann–Whitney U or Kruskal–Wallis followed by pair-wise comparison of treatment means (StatsDirectv2.6.2; Sale, UK). Comparing PCR datasets, Fisher’s exact and χ² tests were utilised as appropriate, in which N is the number of patients, and n is E. coli. Differences were considered significant at p<0.05.

RESULTS
Fosmids extracted from haemagglutinin-positive E. coli in the clone library derived from CRC mucosal E. coli HM358 share a common region containing the afimbrial adhesin afa-1 operon. A total of 968 fosmid clones was generated from randomly sheared 30–50 kb DNA fragments of E. coli HM358, a haemagglutination-positive CRC colonic mucosal isolate. Eight of the resulting 968 E. coli library clones were strongly haemagglutination positive. Analysis of 454-sequence data identified

![Figure 1](http://gut.bmj.com/ on June 24, 2017 - Published by group.bmj.com)
only the full afa-1 operon, coding for afimbrial adhesin Afa-1, as common to the haemagglutination-positive fosmids, plus some additional surrounding transposase and integrate elements (figure 1A; see supplementary file S3, available online only). The afa operon identified contained six open-reading frames encoding for AfaA (a transcriptional regulator), AfaB (a periplasmic chaperone), AfaC (an usher), AfaD (an invasin), DraP (a linker element found in the dra operon) and AfaE-1 (the mannosere-resistant adhesin); figure 1A. PCR targeting a 672 bp amplicon of afaC confirmed the afa operon within the parent E coli HM358 and all eight haemagglutination-positive fosmid clones, whereas eight haemagglutination-negative clones chosen at random from the library and E coli EPI300-T1/pCC1FOS were afa negative (figure 1B). The nucleotide sequence of the HM358 afa-1 cluster was deposited in GenBank; accession no. JN688153.

PCR identified that all eight fosmid-containing haemagglutination-positive E coli were positive for flic, fimA, fimC1, fimH1 and ompC but negative for papC and lpfA.

Increased prevalence of afa in mucosal E coli isolates from CD and CRC patients

PCR for afaC (present in all operons of the afimbrial adhesin family) in a large panel of colonic mucosal E coli isolates showed increased prevalence of afa among isolates from CD (nine of 14 patients; p=0.005, Fisher’s exact test) and CRC (14 of 21; p=0.0009), but not UC (eight of 21), compared with controls (four of 24; table 1). When expressed using E coli as denominator, the presence of afaC was also more common among isolates from CD (39 of 71 isolates (54%)), UC (28/51 (54%)) and CRC (73/120 (60%)) compared with controls (11/39 (28%)); all p≤0.02, with CRC versus controls p=0.0008, χ²; table 2. Like AIEC LF82, ileal CD isolates LF11 and LF86 were negative for afaC, whereas ileal isolates LF10 and LF13 were positive.

Presence of the afa-1 operon correlates with diffuse adherence to and invasion of HEP-2 cells

After 6 h infection of HEP-2 cells, AIEC HM358 and all eight haemagglutination-positive (afa-1 possessing) library clones demonstrated diffuse adherence to HEP-2 characteristic of DAEC (figure 2A–C). No adherence to HEP-2 was observed with eight randomly-selected haemagglutination-negative clones, nor with the K-12 plating strain E coli EPI300-T1/pCC1FOS. All the haemagglutination-positive (afa-1 possessing) E coli invaded HEP-2 cells, at levels similar to those observed for E coli HM358. The haemagglutination-negative (afa-1 negative) clones, afa-negative AIEC LF82, and the K-12-derived EPI300-T1 plating strain, were all substantially less invasive to HEp-2; p<0.0001; Kruskal–Wallis (figure 2D).

Presence of the afa-1 operon correlates with the ability of E coli to adhere to and invade intestinal epithelial cells

The eight haemagglutination-positive E coli clones possessing afa-1 were all shown to adhere to undifferentiated I-407 cells (adhesion relative to HM358 was 0.55±0.13 (mean±SEM) in contrast to non-haemagglutinating, afa-negative E coli, 0.12±0.02; n=4 p<0.0001, Kruskal–Wallis (figure 3A). Similarly, haemagglutination-positive, afa-1 possessing E coli invaded I-407 cells (invasion relative to HM358 was 0.31±0.13) in contrast to haemagglutination-negative, afa-negative clones (0.01±0.01); p<0.0001 (figure 3B). Haemagglutination-positive E coli clones possessing afa-1 also demonstrated greater adhesion to fully differentiated Caco2 cells (afa-positive clones, 0.74±0.14 compared to afa-negative clones, 0.3±0.02); n=4, p<0.0001 (figure 3C). Of note though, three of eight haemagglutination-negative (afa-1 negative) E coli were able to invade differentiated Caco2 cells (figure 3D). The plating strain EPI300-T1/pCC1FOS showed negligible adhesion to and invasion of both cell lines.

Transfection of the full afa-1 operon (pUCafa) into the plating strain resulted in increased adhesion to and invasion of I-407 cells compared to the plating strain transformed with pUC18; p<0.0001, Kruskal–Wallis (figure 3E,F). Similar results were obtained using differentiated Caco2 cells (data not shown).

Assessment of the afaC status of 24 colonic mucosal isolates previously assessed for adherence to and invasion into I-407 epithelial cells showed that nine of 13 afaC-positive isolates were invasive to I-407 cells. However, various afaC-negative isolates, including LF82, were also observed to be invasive for this cell line.

Presence of afa-1 in E coli upregulates VEGF expression by intestinal epithelial cells

VEGF mRNA was upregulated 3.07±0.16-fold in I-407 cells infected with E coli EPI300-T1/pCC1FOS transformed with the afa-1 operon (pUCafa) and 3.71±0.22-fold with AIEC HM358, compared to uninfected cells (N=4, n=3; p<0.001 Kruskal–Wallis). The level of response was similar in cells infected with DAEC C1845 (N=2, n=3; p<0.001); figure 4.

The presence of Afa-1 in mucosally associated E coli does not confer ability to replicate within macrophages or translocate through M cells

In contrast to the parent isolate HM358, no significant intra-macrophage replication was seen with any of the eight haemagglutination-positive (afa-1 possessing) E coli clones (see

### Table 1

<table>
<thead>
<tr>
<th>Total no. of patients</th>
<th>afaC+</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD</td>
<td>14</td>
<td>9</td>
</tr>
<tr>
<td>CRC</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td>UC</td>
<td>21</td>
<td>8</td>
</tr>
<tr>
<td>Controls</td>
<td>24</td>
<td>4</td>
</tr>
</tbody>
</table>

*p Values obtained using Fisher’s exact test (2P component).

### Table 2

<table>
<thead>
<tr>
<th>E coli</th>
<th>afaC+</th>
<th>afaC-</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD</td>
<td>39</td>
<td>32</td>
<td>0.0127</td>
</tr>
<tr>
<td>CRC</td>
<td>73</td>
<td>47</td>
<td>0.0008</td>
</tr>
<tr>
<td>UC</td>
<td>28</td>
<td>23</td>
<td>0.0204</td>
</tr>
<tr>
<td>Controls</td>
<td>11</td>
<td>28</td>
<td></td>
</tr>
</tbody>
</table>

*p Values obtained using χ² test (Yates-corrected).

afaC, gene encoding afimbrial adhesin outer membrane usher protein; CD, Crohn’s disease; CRC, colorectal cancer; UC, ulcerative colitis.
Likewise, seven of the eight haemagglutination-negative clones tested (excepting 4C11), and the *E. coli* EP1300-T1 plating strain containing pCC1Fos was non-adherent. (D) The eight haemagglutination-positive fosmid library clones possessing the *afa*-1 gene cluster, exhibiting diffuse adherence, showed increased ability to invade Hep-2 cells compared to haemagglutination-negative clones. Invasion calculated as percentage of the original inoculum (multiplicity of infection 10) and expressed relative to *E. coli* LF82 previously shown to be invasive in this cell line.2 * p<0.05 and *** p<0.001 when compared to the non-invasive plating strain EP1300-T1 containing pCC1Fos alone (mean±SEM; N=3 experiments, each performed with n=3 replicates; Kruskal–Wallis).

**Figure 2** The presence of the *afa*-1 operon in haemagglutinating *E. coli* correlates with diffuse adherence and invasion to Hep-2 epithelial cells. Giemsa stain of Hep-2 cells infected with *E. coli* strains. (A) All eight haemagglutinin-positive library clones showed diffuse adherence to cell cultures. (B) Eight haemagglutination (HA)-negative fosmid clones chosen at random from the library were non-adherent. (C) Colonic mucosally associated *E. coli* HM358 exhibited a diffusely adherent pattern as per diffusely adherent *E. coli* C1845. The *E. coli* K12 plating strain EP1300-T1 containing pCC1Fos was non-adherent. (D) The eight haemagglutination-positive fosmid library clones possessing the *afa*-1 gene cluster, exhibiting diffuse adherence, showed increased ability to invade Hep-2 cells compared to haemagglutination-negative clones. Invasion calculated as percentage of the original inoculum (multiplicity of infection 10) and expressed relative to *E. coli* LF82 previously shown to be invasive in this cell line.2 * p<0.05 and *** p<0.001 when compared to the non-invasive plating strain EP1300-T1 containing pCC1Fos alone (mean±SEM; N=3 experiments, each performed with n=3 replicates; Kruskal–Wallis).
Similar TNFα levels were released from macrophages by AIEC HM358 (1712±236 pg TNFα/mL) and E coli K-12 strain EPI300-T1/pCC1FOS expressing Afa-1 from pUCAfa (1742±31 pg/mL) compared to uninfected controls (16±5 pg/mL; n=3). All 281 colonic mucosal E coli isolates (including HM358) expressed dsbA and htrA, relevant to intramacrophage replication.

While HM358 (which expresses lpfA) was observed to translocate across M cells, no significant translocation was seen for E coli EPI300-T1 pUCafa, indicating that possession of Afa-1 adhesin does not support FAE transcytosis (see supplementary file S5, available online only).

### Increased prevalence in CD and CRC of DAEC possessing lpfA and fimH relevant to M cell translocation

Screening of 281 colonic mucosally associated E coli demonstrated a striking increased prevalence in CD and CRC of isolates possessing afa together with lpfA (tables 4–7; see
supplementary file S6, available online only). Most isolates (242/281) also expressed *EPI300-T1/pCC1FOS* transformed with *E. coli* invasive were infected for 4 h with either wild-type colorectal cancer adherent, *HM358, Afa/Dr diffusely adhering* *E. coli* C1845 or total RNA extracted. VEGF mRNA measured by quantitative PCR relative to β-actin. Data mean (±SEM) relative to non-infected cells (set at 100%); N=2–4; each n=3 replicates.

*µp<0.05, ***p<0.001 determined by Kruskal–Wallis. AIEC, adherent, invasive *E. coli*; DAEC, diffusely adherent *E. coli*.

**Increased prevalence in CRC and UC of DAEC (afa positive *E. coli*) possessing the pks genotoxicity island relevant to carcinogenesis**

We have recently shown that colonic mucosal *E. coli* from sporadic CRC and IBD commonly express the *pks* genotoxicity island that confers the ability to induce experimental CRC. Screening of *E. coli* for co-expression of *afaC* and *pks* shows a marked increase in *afaC+/pks+ E. coli* in association with CRC and with UC but not CD (tables 4–7).

**DISCUSSION**

This study shows that colonic mucosa-associated *afaC-positive* DAEC are increased in CD and CRC. They adhere to and invade intestinal epithelial cells in culture but also commonly express *lpfA* relevant to M-cell translocation that is more likely to be the major initial route for invasion *in vivo*. Colonic mucosal DAEC isolates also possess *btaA* and *dsbA* relevant to survival within macrophages, part of the characteristic phenotype of CD-associated AIEC.

Afa-expression confers the ability to induce VEGF expression by epithelial cells, relevant to angiogenesis and tumour development and this is confirmed here. We have recently shown that colonic mucosal *E. coli* from patients with IBD and CRC more commonly express the *pks* pathogenicity island whose gene products result in the formation of the metabolite colibactin, a genotoxin with the ability to cause epithelial DNA damage and induce tumours in a mouse model of inflammation-associated CRC. Here we show that colonic mucosal *E. coli* isolates from CRC and UC commonly express both *pks* and *afaC* together. CD *afaC*-expressing *E. coli* isolates, however, did not commonly express *pks*. This may relate to the lack of the increased risk of CRC seen in CD in the absence of colonic involvement, and also raises the possibility that increased *pks* expression by mucosa-associated *E. coli* might be a consequence of colitis, because the presence of *pks* has been shown not to affect *E. coli*-induced inflammation in the mouse IBD model.

Possession of the *afa* operon defines a subgroup of *E. coli* that have a characteristic diffuse adherence pattern to HEp-2

**Table 3  ** *E. coli* uptake and replication within J774-A1 murine macrophages

<table>
<thead>
<tr>
<th>Strain</th>
<th>Uptake of bacteria* (CFU/well×10⁴)</th>
<th>Fold replication 6 h/3 h</th>
<th>Fold replication 24 h/6 h</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>EPI300-T1</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ <em>pCC1FOS</em></td>
<td>9.3±1.6</td>
<td>1.70±0.23</td>
<td>0.69±0.16</td>
</tr>
<tr>
<td>+ <em>pCC1FOS/pUC18</em></td>
<td>11.0±2.1</td>
<td>0.86±0.05</td>
<td>1.21±0.12</td>
</tr>
<tr>
<td>+ <em>pCC1FOS/pUC Afa</em></td>
<td>0.6±0.1†</td>
<td>1.07±0.06</td>
<td>0.27±0.10</td>
</tr>
<tr>
<td><em>HM358</em></td>
<td>5.36±1.1</td>
<td>17.66±3.80§</td>
<td>11.26±2.67§</td>
</tr>
</tbody>
</table>

* Data expressed as means±SEM, determined from N=2–7 independent experiments, with each experiment performed with n=2–3 replicates.
* CFU recovered from lysed macrophages after 3 h (2 h infection followed by 1 h gentamicin treatment).
* Recovered intracellular bacteria from lysed macrophages after 6 h or 24 h, relative to intracellular numbers at 3 h. Statistical analysis was performed using Mann–Whitney U with Bonferroni correction.
* Significantly different from *EPI300-T1/pCC1FOS*; p<0.0001.
* CFU, colony-forming units.

**Table 4  ** Prevalence of *afaC+, lpfA+ E. coli* in patients with CD, colitis and colon cancer compared with controls (with total patients as the denominator)*

<table>
<thead>
<tr>
<th></th>
<th>*afaC+, lpfA+</th>
<th>Total no of patients</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD</td>
<td>8</td>
<td>14</td>
<td>0.0019</td>
</tr>
<tr>
<td>CRC</td>
<td>14</td>
<td>21</td>
<td>0.0001</td>
</tr>
<tr>
<td>UC</td>
<td>6</td>
<td>21</td>
<td>NS</td>
</tr>
<tr>
<td>Controls</td>
<td>2</td>
<td>24</td>
<td></td>
</tr>
</tbody>
</table>

* *p* Values obtained using Fishers exact test (2P component).
† Presence or absence of genes is based on PCR assays.

**Table 5  ** Presence of *afaC+, lpfA+ E. coli* in CD, colitis and colon cancer compared with controls (using total number of *E. coli* as the denominator)*

<table>
<thead>
<tr>
<th></th>
<th>*afaC+, lpfA+</th>
<th>Total no of <em>E. coli</em></th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD</td>
<td>30</td>
<td>71</td>
<td>0.0011</td>
</tr>
<tr>
<td>CRC</td>
<td>51</td>
<td>120</td>
<td>0.0005</td>
</tr>
<tr>
<td>UC</td>
<td>15</td>
<td>51</td>
<td>NS</td>
</tr>
<tr>
<td>Controls</td>
<td>4</td>
<td>39</td>
<td></td>
</tr>
</tbody>
</table>

* *p* Values obtained using χ² test (Yates-corrected).
† Presence or absence of genes is based on PCR assays.

*afaC*, gene encoding afimbrial adhesin outer membrane usher protein; CD, Crohn’s disease; CRC, colorectal cancer; *E. coli*, gene encoding long polar fimbrial protein; UC, ulcerative colitis.
epithelial cells and that includes UPEC and diarrhoeagenic DAEC strains. Sequencing revealed that the *afa*–1 operon identified in our colonic mucosal isolate shares the same linker element *draP* as in the *Dr* operon, which encodes the Afa-related Dr adhesin. Transfection of the *afa*–1 operon into a non-pathogenic *E coli* EP1300-T1 (K-12) strain conferred the ability not only to adhere to HEP-2 but also to invade this and other cell lines, thus conferring part of the CD AIEC phenotype. The wild-type strain HM358 shows still greater ability to adhere to and invade than the *afa*-1-transfected *E coli* K-12 strain, implying that other adhesins/invasins are also involved and this is confirmed by invasion to I-407 seen in occasional *afa*-negative isolates.

The *afa*–1 operon does not confer the other phenotypic property reported for AIEC and relevant to CD pathogenesis, that is, replication within macrophages. Two genes *btrA* and *dsbA* are already known to support AIEC LF82 replication within macrophages, both encoding stress tolerance proteins that reduce bacterial killing within phagolysosomes. Colonic mucosal DAEC isolates from CD and CRC patients are shown here also to possess *btrA* and *dsbA* needed to complete the AIEC phenotype.

UPEC with the DAEC phenotype have previously been shown to invade epithelial cells *in vitro* but it has been uncertain whether or not they invade fully differentiated intestinal cells. It should be noted that the same also applies to AIEC isolates from CD, which have not been convincingly seen within intestinal epithelial cells in human mucosal samples. Indeed, even bona fide intestinal pathogens such as *Salmonella* spp., *Shigella* spp., Mycobacteria and Cholera vibrios require, as their initial points of entry, translocation across the specialised M cells that are sites for the earliest lesions (aphthoid ulcers) in CD. It is intriguing that Peyer’s patches and lymphoid follicles affected by early Crohn’s lesions have surrounding neovascularisation that may be seen as a ‘red ring sign’ on colonoscopy and enhanced by previous fluorescein injection, a phenomenon that could plausibly reflect angiogenesis driven by *Afa*-positive *E coli*.

Mucosa-associated AIEC have been reported particularly in the ileum of CD patients, although they also occur in the colon and studies that include ileal and colonic samples from the same individuals have shown mucosa-associated *E coli*, if present, throughout the terminal ileum and colon. Their adhesion to ileal mucosa requires overexpression of CEACAM6, occurring in response to inflammation. The ‘paradigm’ ileal AIEC LF82 is *afa* negative, although other ileal isolates tested were found to be *afa* positive. It seems likely from the studies presented here, that DAEC possessing *afa*-1 may be better suited to colonisation of the colonic environment.

Members of the Afa/Dr family commonly use a glycosylphosphatidylinositol-anchored protein, the decay-accelerating factor (DAF), as a cellular receptor. AIEC are apically localised in differentiated Caco2 cells. Afa/Dr adhesins also bind variably to CEACAM-1, CEACAM-5 (CEA) and CEACAM-6. DAEC binding induces the recruitment of DAF and CEA family receptors around adhering bacteria by a lipid raft-dependent mechanism, which initiates internalisation and cell signalling. Both CEACAM-6 and DAF are upregulated in IBD and CRC and thus may serve as Afa/Dr receptors. Colonic mucosal DAEC colonisation. DAEC infection of the human colonic T84 cell line promotes IL-8 release and neutrophil transmigration, which in turn induces TNF-α and IL-1β-dependent upregulation of DAF.

It has been shown previously that DAEC are partly resistant to phagocytosis by neutrophils. Recombinant *E coli* expressing Afa/Dr adhesins, including Afa-1, Afa-III, Dr and F1845, adhere to neutrophils but remain extracellular. The present study suggests that Afa also confers resistance to uptake by macrophages.

It is interesting that the presence of Afa-1, although conferring the ability to invade some epithelial cell lines, does not confer the ability to translocate across M cells. Although this has been shown here using an *in vitro* M-cell model, we have previously shown excellent correlation between results obtained in this model for human colonic mucosa-associated *E coli* and their ability to translocate across human FAE in ileal explants cultured in Ussing chambers. M cells are phagocytic *in vitro*, even for inert particles, and it may be that translocation across M cells bears more relationship to phagocytosis than to invasion. Translocation is dependent not only on the possession of LpfA but also on interaction between FimH and its receptor, GP2, selectively expressed by M cells.

### Table 6

<table>
<thead>
<tr>
<th></th>
<th>Total no of patients</th>
<th><em>afaC</em>, <em>pkS</em>+</th>
<th><em>afaC</em>, <em>pkS</em>–</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD</td>
<td>14</td>
<td>4</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>CRC</td>
<td>21</td>
<td>11</td>
<td>0.0015</td>
<td></td>
</tr>
<tr>
<td>UC</td>
<td>21</td>
<td>8</td>
<td>0.0222</td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>24</td>
<td>2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p Values obtained using Fisher’s exact test (2P component).

†Presence or absence of *afaC* and *pkS* is based on PCR assay.

afa* C, gene encoding afimbrial adhesin outer membrane usher protein; CRC, colorectal cancer; UC, ulcerative colitis.

### Table 7

<table>
<thead>
<tr>
<th></th>
<th><em>afaC</em>+</th>
<th><em>afaC</em>–</th>
<th><em>pkS</em>+</th>
<th><em>pkS</em>–</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD</td>
<td>13</td>
<td>58</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRC</td>
<td>35</td>
<td>85</td>
<td>0.0119</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UC</td>
<td>17</td>
<td>34</td>
<td>0.0082</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>30</td>
<td>36</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p Values obtained using χ² test (Yates-corrected).

†Presence or absence of *afaC* and *pkS* is based on PCR assay.

afa* C, gene encoding afimbrial adhesin outer membrane usher protein; CD, Crohn’s disease; CRC, colorectal cancer; UC, ulcerative colitis.
patients with CD did not find significant differences in afaE-3 or afa/draB in CD patients nor in afa/draB frequency between AIEC/non-AIEC isolates.10–11 However, the same research group recently reported afaE-3 association in approximately 24% of E. coli isolates of newly diagnosed CD patients.10 One major difference with those studies is the choice of primers used to screen isolates. The primers used in the present study target all afa strains, irrespective of the afaE subtype.25

DAEC not only promote VEGF secretion by epithelial cells but also induce epithelial–mesenchymal transition (EMT)20 implicated in carcinoma progression.51 EMT contributes to intestinal fibrosis in a mouse model of CD, and EMT markers have also been detected in Crohn’s fistulas.52–53 VEGF/VEGFR2 signalling similarly links between inflammation and colitis-associated cancer and promotes tumour growth in vitro.30

The association between colonic mucosal DAEC and CRC adds to growing evidence linking bacteria with CRC pathogenesis. We have previously speculated that bacterial–epithelial interactions might be particularly important in progression from dysplasia to cancer.54 Dysplastic mucosa is usually goblet cell depleted and lacks overlying mucus. Moreover, the underlying glycocalyx is sparse. It is therefore much easier for bacteria to gain direct contact with the mucosal surface, a location that is relatively sterile in the normal colon. This would allow interaction between bacterial components and Toll-like receptors, with subsequent downstream signalling via MyD88 to nuclear factor κB activation. Epithelial nuclear factor κB activation, rather than histological inflammation, has been implicated as the mechanism for inflammation-associated CRC,55 moreover MyD88-deficient mice cross-bred onto ApoE mice show markedly reduced tumour formation.56 The ability of pks-expressing E. coli to damage DNA probably makes these bacteria particularly dangerous to the host if they become established in close contact with the colonic epithelium. If epithelial-associated bacteria such as DAEC play a causative role in CRC and CD then dietary consumption of soluble plant fibres that prevent mucosal recruitment of bacteria5, 28 may be protective against both conditions.

The strong association between colonic mucosal afa-positive DAEC and both CD and sporadic CRC suggests a possible role for DAEC in the pathogenesis of both conditions, but does not imply that the mechanisms involved will be the same for both. Therefore, co-expression of IpfA, important for M-cell translocation, is relevant to CD but unlikely to be relevant to CRC. Co-expression of the genotoxicity island pks, possession of which confers the ability to induce breaks in double-stranded DNA, is relevant to CRC but not obviously to IBD. Therefore, the possible mechanisms for E. coli-induced carcinogenesis may be independent from any effects on IBD pathogenesis. The link with Afa expression probably relates to the propensity for DAEC to colonise the colonic mucosa although studies have yet to be performed to address this directly. Intervention studies will ultimately be needed to assess the role of DAEC in the pathogenesis of CD and CRC.

**Contributors** BJC and JMR contributed equally. BJC, JMR and CW obtained funding and with JRM, designed research. AA, BJC, CC, CLR, FS, MKF, MP-H, PKF, PK and NH performed experiments. BJC, CW, MP-H, MKF, JRM and JMR performed analyses and interpretation of data. BJC, JMR and MP-H drafted the manuscript, with critical revision by all authors.

**Funding** MPH, FS, PKF and PK were supported by the NIHR Biomedical Research Centre for Microbial Diseases, Liverpool (O1C01). MKF was funded by Crohn’s and Colitis UK (M08/1). AA was supported by Dammann University, Saudi Arabia. JRM and CC were supported by Science Foundation Ireland. BJC acknowledges funding from the North West Cancer Research Fund, UK (CR727) and the support of the European Science Foundation, in the framework of the Research Networking Programme, the European Network for Gastrointestinal Health Research. The sponsors had no role in the study design, nor in the collection and interpretation of data.

**Competing interests** JMR is has been a member of advisory boards for Atlantic, Procter & Gamble and Falk, has received speaking honoraria from Abbott, Falk, Ferring, Glaxo Smith Kline, Procter & Gamble and Schering Plough and, with the University of Liverpool and Proxsys PLC, holds a patent for use of a soluble fibre preparation as maintenance therapy for Crohn’s disease. BJC has received a speaking honorarium from Amgen Inc.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** We affirm that all data necessary for a reader of Gut to understand and evaluate the conclusions of the paper will be archived in an approved database and made available to any reader. After publication, all reasonable requests for materials and data will be fulfilled. There is a University of Liverpool NIMR using the human mucosal E. coli. We can confirm that to date all requests from researchers within the international scientific community for isolates from the Liverpool archive have been granted and materials supplied.

**Accession number** The nucleotide sequence of the afa-1 operon from E. coli HM358 has been submitted to GenBank (http://www.ncbi.nlm.nih.gov/Genbank/); accession number IN668153.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adopt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**


Gut microbiota


Colonic mucosa-associated diffusely adherent *afaC*+ *Escherichia coli* expressing *lpfA* and *pkS* are increased in inflammatory bowel disease and colon cancer

Maelle Prorok-Hamon, Melissa K Friswell, Abdullah Alsowied, Carol L Roberts, Fei Song, Paul K Flanagan, Paul Knight, Caroline Codling, Julian R Marchesi, Craig Winstanley, Neil Hall, Jonathan M Rhodes and Barry J Campbell

*Gut* published online July 11, 2013

Updated information and services can be found at: [http://gut.bmj.com/content/early/2013/07/10/gutjnl-2013-304739](http://gut.bmj.com/content/early/2013/07/10/gutjnl-2013-304739)

These include:

**Supplementary Material**

Supplementary material can be found at: [http://gut.bmj.com/content/suppl/2013/07/10/gutjnl-2013-304739.DC1](http://gut.bmj.com/content/suppl/2013/07/10/gutjnl-2013-304739.DC1)

**References**

This article cites 56 articles, 25 of which you can access for free at: [http://gut.bmj.com/content/early/2013/07/10/gutjnl-2013-304739#BIBL](http://gut.bmj.com/content/early/2013/07/10/gutjnl-2013-304739#BIBL)

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Open access (354)
- Colon cancer (1547)
- Crohn's disease (932)
- Irritable bowel syndrome (327)
- Ulcerative colitis (1113)

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)